Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Interleukin-23 Inhibitors (IL-23i) in the Treatment of Inflammatory Bowel Disease in China: A Multicenter, Single-Arm, Prospective, Observational Real-World Study

NCT07184138 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.

NCT NCT07184138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07184138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Interleukin-23 Inhibitors (IL-23i) in the Treatment of Inflammatory Bowel Disease in China: A Multicenter, Single-Arm, Prospective, Observational Real-World Study
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
November 1, 2028
Enrollment
178 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

inflamatory bowel disease (crohn's and ulcerative colitis)